Get startedLog in
    Picture of IPI Legacy Liquidation Co logo

    IMPLQ — IPI Legacy Liquidation Co News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    All News

    Brief: Impel Neuropharma Inc - Planned Initiation Of Inp105 Proof-Of-Concept Study For Autism Spectrum Disorder In Q1 2022

    Picture of IPI Legacy Liquidation Co logoIPI Legacy Liquidation Co
    18/01/2022 13:40
    Jan 18 (Reuters) - Impel Neuropharma Inc  IMPL.O :
    * IMPEL NEUROPHARMA INC - PLANNED INITIATION OF INP105
PROOF-OF-CONCEPT STUDY FOR AUTISM SPECTRUM DISORDER IN Q1 2022;
RESULTS ANTICIPATED Q4 2022
    * IMPEL NEUROPHARMA INC - TRUDHESA NASAL SPRAY FOR ACUTE
MIGRAINE
DELIVERED STRONG Q4 2021 LAUNCH WITH 4,200 (TRX) PRESCRIPTIONS

Source text for Eikon:  ID:nGNX61qJ8P 
Further company coverage:  IMPL.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on IPI Legacy Liquidation Co

    See all news